Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study

Bristol-Myers Squibb Company BMY suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its primary endpoint.